Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab Ozogamicin ± DLI for Relapsed B-ALL/LBL Post-Transplant
NCT06861348Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Mar 2025
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of inotuzumab ozogamicin in B cell acute lymphoblastic leukemia (B-ALL), lymphoblastic lymphoma (LL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
inotuzumab ozogamicin
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT06861348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06861348.